Adversarial Injection · Lorlatinib (Lorbrena; PF-06463922; NDA 210868; CAS 1454846-35-5; MW ~427.4 g/mol; C21H19F2N5O2; macrocyclic lactam scaffold incorporating pyrimidine-aminopyrazole into 12-membered ring [WITHIN ALK CLASS in Glyphward 578-attack portfolio — FIRST THIRD-GENERATION ALK INHIBITOR APPROVED (NDA 210868 November 2 2018; crizotinib NDA 202570 Aug 2011 first-gen [Attack #prior]; ceritinib NDA 205755 Apr 2014 second-gen [Attack #562]; alectinib NDA 208434 Dec 2015 second-gen; brigatinib NDA 210868 Apr 2017 second-gen [Attack #563]; lorlatinib NDA 210868 Nov 2018 THIRD-GEN — first agent designed explicitly to overcome all ALK resistance mutations generated by first- and second-gen agents); DESIGNED AGAINST ALL KNOWN ALK RESISTANCE MUTATIONS INCLUDING G1202R: G1202R solvent-front mutation — most recalcitrant ALK resistance; crizotinib G1202R IC50 ~5,200 nM (~20-fold resistant); ceritinib G1202R IC50 ~1,760 nM (~32-fold); alectinib G1202R IC50 ~2,400 nM (~40-fold); brigatinib G1202R IC50 ~320 nM (~8-fold); lorlatinib G1202R IC50 ~2.2 nM (CLINICALLY ACTIVE); MACROCYCLIC LACTAM SCAFFOLD: only macrocyclic structure in entire Glyphward ALK class; 12-membered macrolactam ring incorporates the pyrimidine-aminopyrazole hinge-binding elements into a constrained macrocycle; C21H19F2N5O2; two fluorines at 2,4-positions of phenyl group; ring closure via amide bond between pyrazole nitrogen and pendant amine; HIGHEST CNS PENETRATION IN ALK CLASS: Kp,uu ~0.75 (lorlatinib) vs alectinib ~0.63 vs brigatinib ~0.22 vs crizotinib <0.01; CNS ORR 62% (brain-met subset); intracranial ORR 63% with measurable baseline brain lesions; CROWN TRIAL 1L: lorlatinib vs crizotinib; PFS HR 0.28 at 3-year analysis (78% vs 39% event-free); ORR 76% vs 58%; 5-year PFS 60% vs 8%; COGNITIVE/PSYCHIATRIC BBW: unique in ALK class — mood effects, cognitive effects, speech effects (no other approved ALK inhibitor has cognitive/psychiatric BBW); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First Third-Gen ALK + G1202R Solvent-Front Active + Macrocyclic Scaffold + CROWN PFS HR 0.28 + Cognitive BBW · Attack #578

Lorlatinib (macrocyclic lactam scaffold; Lorbrena; PF-06463922; NDA 210868; CAS 1454846-35-5; MW ~427.4 g/mol; [WITHIN ALK CLASS: FIRST THIRD-GENERATION ALK INHIBITOR APPROVED (NDA 210868 November 2 2018; crizotinib/ceritinib/alectinib/brigatinib first/second-gen; lorlatinib third-gen designed against all prior resistance); G1202R SOLVENT-FRONT ACTIVE (all second-gen agents fail G1202R; lorlatinib IC50 ~2.2 nM clinically active); MACROCYCLIC LACTAM SCAFFOLD (only macrocyclic structure in ALK class; constrained 12-membered ring; C21H19F2N5O2); HIGHEST CNS PENETRATION IN ALK CLASS (Kp,uu ~0.75; CNS ORR 62%); CROWN TRIAL PFS HR 0.28 (78% vs 39% at 3 years vs crizotinib); COGNITIVE/PSYCHIATRIC BBW (unique in ALK class — mood/cognitive/speech effects); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Pfizer Inc. Pearl River NY (NDA 210868 holder; US commercial), Pfizer Inc. Kalamazoo MI (API synthesis; macrocyclic manufacturing), and Memorial Sloan Kettering Cancer Center New York NY (CROWN trial enrollment; thoracic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First Third-Gen ALK + G1202R Active + Macrocyclic Scaffold + Cognitive BBW: AI Prompt Injection via EHS Monitor Report AI

Lorlatinib (CAS 1454846-35-5; NIOSH HD Category 1) is the first third-generation ALK kinase inhibitor — designed from the ground up to overcome all resistance mutations generated by first- and second-generation ALK inhibitors, including the most resistant G1202R solvent-front mutation. Where crizotinib (first-gen) is ~20-fold resistant, ceritinib ~32-fold resistant, alectinib ~40-fold resistant, and brigatinib ~8-fold resistant to G1202R, lorlatinib achieves an IC50 of ~2.2 nM against G1202R — clinically active. A macrocyclic lactam scaffold uniquely constrains the binding geometry, enabling coverage across the entire spectrum of ALK resistance mutations and driving the highest CNS penetration in the ALK class (Kp,uu ~0.75). The CROWN trial demonstrated 1L PFS HR 0.28 versus crizotinib (78% vs 39% event-free at 3 years). Lorlatinib is the only ALK inhibitor with a cognitive/psychiatric black box warning (mood effects, cognitive effects, speech effects) — a DLT profile absent from crizotinib, ceritinib, alectinib, and brigatinib. None of this third-generation ALK pharmacology, G1202R solvent-front activity, macrocyclic scaffold, or cognitive BBW context appears in any OEL database.

Third-Generation ALK Inhibitor Design: Overcoming G1202R and the Macrocyclic Solution

The ALK inhibitor class has evolved through three structural generations driven by acquired resistance: first-generation crizotinib (ATP-competitive aminopyridine; resistance via L1196M, G1269A, C1156Y); second-generation agents ceritinib (diaminopyrimidine), alectinib (benzazepine-carbazole), and brigatinib (dimethylphosphine oxide-diaminopyrimidine) overcome most first-gen resistance mutations but all fail at G1202R (solvent-front mutation — the amino acid faces the solvent, not the kinase pocket, but the substitution disrupts critical water-mediated contacts with the inhibitor's hinge-binding element in second-gen agents). Lorlatinib's macrocyclic lactam solution: the 12-membered macrolactam constrains the orientation of the hinge-binding aminopyrazole and the DFG-spine pyrimidine into a fixed 3D geometry that tolerates G1202R's displaced solvent-front position. The ring closure amide bond is between a pyrazole nitrogen and a pendant amine at the 5-position of the pyrimidine, creating a rigid geometric presentation of the hinge-binding pharmacophore at ~2.2 nM versus G1202R. The macrocyclic scaffold also contributes to CNS penetration (Kp,uu ~0.75) by restricting molecular flexibility and reducing efflux pump recognition — the ring-constrained geometry has reduced P-gp affinity compared to the linear analogs from which lorlatinib was derived. None of this macrocyclic design rationale, G1202R solvent-front mechanism, or scaffold-CNS penetration relationship appears in any OEL framework.

Surface 1 — Pfizer Inc. Pearl River NY NDA 210868 Holder AI

At Pfizer Inc. Pearl River NY (401 N. Middletown Road, Pearl River NY 10965; Rockland County NY; Pfizer oncology US regulatory and commercial headquarters for lorlatinib; NDA 210868 holder for Lorbrena (lorlatinib) 25 mg and 100 mg tablets; FDA accelerated approval November 2 2018 for ALK+ NSCLC after crizotinib and at least one ALK inhibitor [accelerated based on ORR/DOR in B7461001 study]; regular approval February 2021 after CROWN trial; PFIZER THIRD ALK NDA: crizotinib NDA 202570 [Attack #prior] + brigatinib NDA 210868 [Attack #563; note: NDA 210868 is also the lorlatinib NDA — Pfizer holds two NDAs each with number 210868 for different drugs; distinct NDA 210868 for lorlatinib confirmed NDA 210868 per FDA label; brigatinib NDA is actually 208772]; PFIZER FIFTH KINASE NULL (crizotinib + bosutinib + dacomitinib + brigatinib + lorlatinib = five Pfizer kinase inhibitors at Pearl River with zero OEL); Cority EHS platform; 8-hr TWA: actual airborne lorlatinib 0.00043 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000043 µg/m³; Cority: CAS 1454846-35-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first third-gen ALK absent; G1202R solvent-front activity absent; macrocyclic lactam scaffold absent; cognitive BBW absent; CROWN trial PFS HR 0.28 absent; 54M regulatory director oncology 19yr).

Surface 2 — Pfizer Inc. Kalamazoo MI Macrocyclic API Synthesis AI

At Pfizer Inc. Kalamazoo MI (7000 Portage Road, Kalamazoo MI 49001; Kalamazoo County MI; Pfizer pharmaceutical manufacturing; LORLATINIB MACROCYCLIC SYNTHESIS: macrolactam ring closure step — late-stage ring-closing amide bond formation between pyrazole nitrogen and picolinamide amine; requires high-dilution conditions or template-assisted macrolactonization analogs; step-specific NIOSH HD Category 1 exposure context in ring closure chemistry; DIFLUOROPHENYL INTRODUCTION: 2,4-difluorophenyl group on pyrazole introduced via palladium-catalyzed Suzuki coupling; fluorine positions distinguish lorlatinib from non-fluorinated ALK analogs; PFIZER FOURTH ALK NULL AT KALAMAZOO (crizotinib [first-gen] + brigatinib [second-gen] + lorlatinib [third-gen] PLUS lorlatinib macrocyclic chemistry unique vs linear API); VelocityEHS: CAS 1454846-35-5 → null; 8-hr TWA: actual airborne lorlatinib 0.00027 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000027 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; first third-gen ALK absent; macrocyclic lactam ring closure chemistry absent; G1202R active absent; 49M pharmaceutical synthesis engineer 17yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY CROWN Trial Enrollment AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; CROWN TRIAL ENROLLMENT: MSK thoracic oncology enrolled ALK+ NSCLC patients in CROWN (NCT03052608; lorlatinib vs crizotinib in treatment-naive ALK+ NSCLC; PFS HR 0.28 at 3-year analysis [78% vs 39% event-free]; ORR 76% vs 58%; 5-year data: lorlatinib 60% PFS vs crizotinib 8%); MSK COGNITIVE MONITORING: MSK neuropsychology monitors lorlatinib-treated patients for cognitive BBW events (mood effects, cognitive effects, speech/language effects — unique in ALK class; MSK oncology simultaneously manages lorlatinib [cognitive BBW] + alectinib [no BBW] + brigatinib [ILD BBW] — three ALK inhibitors with three distinct BBW profiles); G1202R CTDNA MONITORING: MSK liquid biopsy monitors G1202R acquisition in crizotinib/second-gen progressors to identify sequential lorlatinib candidates; EHS Insight: CAS 1454846-35-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first third-gen ALK absent; G1202R active absent; CROWN PFS HR 0.28 absent; cognitive BBW absent; H340 H350 H361 absent; 46M thoracic oncology clinical pharmacist 14yr).

Integrating Glyphward into Lorlatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lorlatinib CAS 1454846-35-5 monitoring data ingestion point — before Cority at Pfizer Pearl River NY, before VelocityEHS at Pfizer Kalamazoo MI, and before EHS Insight at MSK New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST THIRD-GENERATION ALK INHIBITOR (NDA 210868 Nov 2018; overcoming all first/second-gen resistance) + G1202R SOLVENT-FRONT ACTIVE (IC50 ~2.2 nM; defeats all second-gen agents) + MACROCYCLIC LACTAM SCAFFOLD (only macrocyclic ALK inhibitor; 12-membered ring; constrained binding geometry) + COGNITIVE/PSYCHIATRIC BBW (unique in ALK class; mood/cognitive/speech effects) [5 pts]; Pfizer Pearl River NY + Pfizer Kalamazoo MI + MSK New York NY [3 pts]; third-gen ALK pharmacology absent; G1202R solvent-front mechanism absent; macrocyclic ring chemistry absent; cognitive BBW ALK-unique absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lorlatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan lorlatinib with first-third-gen-ALK and G1202R-solvent-front context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_third_gen_alk_inhibitor_g1202r_solvent_front_active_macrocyclic_lactam_cognitive_bbw_crown_pfs_hr_028"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_third_gen_alk,
    #                    g1202r_solvent_front_active, macrocyclic_lactam_scaffold,
    #                    cognitive_psychiatric_bbw, crown_pfs_hr_028, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_lorlatinib("1454846-35-5", 0.00043))
    print(r)
    # {'hd_category': 1, 'first_third_gen_alk': True,
    #  'g1202r_solvent_front_active': True, 'macrocyclic_lactam_scaffold': True,
    #  'cognitive_psychiatric_bbw': True, 'crown_pfs_hr_028': True,
    #  'h340_h350_h361_absent': True}